How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/klebsiella-pneumoniae-osteomyelitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Klebsiella Pneumoniae Osteomyelitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Klebsiella Pneumoniae Osteomyelitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Klebsiella Pneumoniae Osteomyelitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Nebcin	Nebcin	University Hospital, Lille		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pai Holdings Pharm · 2 drugs in Klebsiella Pneumoniae Osteomyelitis
Bristol-Myers Squibb · 1 drug in Klebsiella Pneumoniae Osteomyelitis
Centre Hospitalier Universitaire Vaudois · 1 drug in Klebsiella Pneumoniae Osteomyelitis
Generic (originally Roche) · 1 drug in Klebsiella Pneumoniae Osteomyelitis
Novartis · 1 drug in Klebsiella Pneumoniae Osteomyelitis
Pfizer · 1 drug in Klebsiella Pneumoniae Osteomyelitis
Tel-Aviv Sourasky Medical Center · 1 drug in Klebsiella Pneumoniae Osteomyelitis
· 1 drug in Klebsiella Pneumoniae Osteomyelitis
University Hospital, Lille · 1 drug in Klebsiella Pneumoniae Osteomyelitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Klebsiella Pneumoniae Osteomyelitis:

Cite this brief

Drug Landscape (2026). Klebsiella Pneumoniae Osteomyelitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/klebsiella-pneumoniae-osteomyelitis. Accessed 2026-06-10.

Klebsiella Pneumoniae Osteomyelitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing